OBJECTIVE: To define the possible effects of gastric electrical stimulation (GES) for gastroparesis on pancreatic function, we performed 2 related human studies. METHODS: Fecal elastase values were compared in 2 patient groups: (1) GES devices ON and (2) GES devices OFF and (2) in 3 control groups: (1) no response (NR) to prokinetic medications, (2) positive response (RES) to medications, and (3) normal controls. Polypeptide levels in 7 of 9 GES patients with device ON and OFF, elastase results, GI symptoms (TSS), and heart rate variability (HRV) were compared by paired t tests and/or ANOVA and reported as mean +/- SE. RESULTS: Elastase was different for GES-ON and OFF (508.0 +/- 92.2 vs. GES-OFF 378.6 +/- 87.4, P < 0.05). Elastase was lower in medication NR and RES than in normal controls. Postprandial pancreatic polypeptide was greater with GES ON than OFF (P = 0.07). HRV revealed a lower percentage of change with device ON versus OFF (44.2 +/- 5.5 vs. 48.5 +/- 5.2, P = 0.08) and lower TSS with ON versus OFF (15.9 +/- 4.5 vs. 25.7 +/- 5.3, P < 0.05). CONCLUSIONS: GES improves exocrine pancreatic release, effects autonomic control, and improves GI symptoms, suggesting a possible role for GES in the treatment of pancreatic insufficiency associated with gastroparesis.
OBJECTIVE: To define the possible effects of gastric electrical stimulation (GES) for gastroparesis on pancreatic function, we performed 2 related human studies. METHODS: Fecal elastase values were compared in 2 patient groups: (1) GES devices ON and (2) GES devices OFF and (2) in 3 control groups: (1) no response (NR) to prokinetic medications, (2) positive response (RES) to medications, and (3) normal controls. Polypeptide levels in 7 of 9 GES patients with device ON and OFF, elastase results, GI symptoms (TSS), and heart rate variability (HRV) were compared by paired t tests and/or ANOVA and reported as mean +/- SE. RESULTS: Elastase was different for GES-ON and OFF (508.0 +/- 92.2 vs. GES-OFF 378.6 +/- 87.4, P < 0.05). Elastase was lower in medication NR and RES than in normal controls. Postprandial pancreatic polypeptide was greater with GES ON than OFF (P = 0.07). HRV revealed a lower percentage of change with device ON versus OFF (44.2 +/- 5.5 vs. 48.5 +/- 5.2, P = 0.08) and lower TSS with ON versus OFF (15.9 +/- 4.5 vs. 25.7 +/- 5.3, P < 0.05). CONCLUSIONS: GES improves exocrine pancreatic release, effects autonomic control, and improves GI symptoms, suggesting a possible role for GES in the treatment of pancreatic insufficiency associated with gastroparesis.
Authors: Michael Camilleri; Henry P Parkman; Mehnaz A Shafi; Thomas L Abell; Lauren Gerson Journal: Am J Gastroenterol Date: 2012-11-13 Impact factor: 10.864
Authors: Andrew F R Dixon; Carel W le Roux; Mohammad A Ghatei; Stephen R Bloom; Toni L McGee; John B Dixon Journal: Obes Surg Date: 2011-12 Impact factor: 4.129
Authors: Michael Camilleri; Braden Kuo; Linda Nguyen; Vida M Vaughn; Jessica Petrey; Katarina Greer; Rena Yadlapati; Thomas L Abell Journal: Am J Gastroenterol Date: 2022-06-03 Impact factor: 12.045
Authors: E Soffer; T Abell; Z Lin; A Lorincz; R McCallum; H Parkman; S Policker; T Ordog Journal: Aliment Pharmacol Ther Date: 2009-07-02 Impact factor: 8.171
Authors: Thomas L Abell; Goro Yamada; Richard W McCallum; Mark L Van Natta; James Tonascia; Henry P Parkman; Kenneth L Koch; Irene Sarosiek; Gianrico Farrugia; Madhusudan Grover; William Hasler; Linda Nguyen; William Snape; Braden Kuo; Robert Shulman; Frank A Hamilton; Pankaj J Pasricha Journal: Neurogastroenterol Motil Date: 2019-10-04 Impact factor: 3.598